Colorectal Cancers Screening in the General Population: Focusing by Elhabachi, Boumediene & Ben Brahim, Mama Sidelmrabet






Colorectal cancers, Screening in the general 
population: Focusing 
Type of article: Review 
Boumediene Elhabachi; Mama Sidelmrabet Ben Brahim 
Faculty of medicine University of Sidi Bel Abbes, Algeria 
CHU Dr Hassani A.E.K, Algeria 
Abstract 
Colorectal cancers are common throughout the world, although their incidence varies across 
continents and countries. 28% of these cancers are rectal, and two-thirds of the remaining 72% are 
of left colonic location. Screening and prevention have proven effective in reducing the incidence 
of these cancers and their mortality. The best screening results in the so-called average-risk general 
population have been obtained in the USA, where the first-line endoscopy is the gold standard 
when in other countries, especially European ones; screening was done by the search for occult 
blood in the stool. This group, however, became heterogeneous due to the intervention of 
environmental factors and co-morbidities; a colonoscopy is then proposed to those subjects 
considered at average risk. Virtual colonoscopy has excellent sensitivity and specificity for one-
centimeter polyps. The serrated polyps, pre-cancerous lesions predominating on the right, are more 
difficult to detect. 
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1. Introduction 
Colorectal Cancer (CRC) is one of the most common cancers worldwide with 1 
million new cases a year [1]. From the epidemiological point of view, the right 
colon extends to the splenic fissure, as well as to the left colic angle (without 
including it) and the left colon  extends from the left colic angle to the-sigmoid 
hinge [2]. Seventy-two percent of these cancers are colonic, of which two-thirds 
are in the left colon, and 28% are rectal. The localization of the lesions is of great 
importance in terms of diagnosis, surveillance, pathophysiology, and obviously 
therapeutic. 
Colorectal cancers are sporadic in 70 to 80% of cases [3]. This is essentially the 
average risk group aged 50 to 75 years. Subjects at average risk are exposed 
differently to environmental hazards and co-morbidities. Several scores have been 
proposed to evaluate the risk in this population including the Kaminski score. A 
colonoscopy is proposed to them as for the high-risk group. "True" average risk 
subjects are screened for a trade-off between benefit and risk of the available 
means. The cost of CRC is getting more and more expensive, and this trend is 
confirmed for years to come [4]. This cancer threatens the man in his life and 
society in its economy, hence the interest of the issue. 







With more than one million cases diagnosed and 500,000 deaths [1] per year 
worldwide, this cancer is a public health problem [5]. Colorectal cancer (CRC) is 
the fourth leading cause of death in men and the third one in women worldwide. 
Its incidence increases with age [6]. The average age at diagnosis in men (60-65 
years) is slightly earlier than in women (65-70 years) [7]. In men, the peak of 
mortality is between 65 and 70 years old and in the women between 70 and 75 
years old [5, 7]. CRC is more common in industrialized countries than in 
developing ones [5]. 
The CRC is the third most common cancer in the US and the third leading cause 
of cancer death [8, 9], while its incidence has declined significantly over the last 
four decades [8]. This decrease in incidence is due to screening programs but also 
the trend towards healthier lifestyles [10]. In 2018, newly diagnosed cases were 
estimated to be at 140,250, say 8.1% of all new cancer cases, and a death rate of 
50,630, or 8.3% of all cancer deaths [11-13]. Between 2004 and 2008, the 
incidence in men was 55 per 100,000 with a mortality of 20.7 per 100,000 and 41 
per 100,000 among women with a mortality of 14.5 per 100,000, while 
emphasizing that the incidence was higher for African-Americans [9]. The 5-year 
survival during the period 2001-2007 averaged 65.5% for men (55% for African-
Americans) and 64.5% for women (56.9% for Afro-Americans) [14]. 
3. The justification for screening 
Screening involves detecting colorectal cancer at an early stage at which the 
cancer is potentially curable. 
Prevention aims to diagnose and remove precancerous lesions to reduce the 
incidence of colorectal cancer. 
The term "screening" is often used to define the actual screening but also, by the 
excess of language, prevention. 
For justifying screening: 
A sufficiently sensitive, specific, and non-invasive screening tool is needed. 
It must concern a sufficiently frequent and serious pathology. 
It is necessary to have an effective therapeutic means of the detected lesions. 
The CRCs meet all these criteria [15]. They are frequent, and their screening has 
made it possible to reduce morbidity and mortality by CRC. Early cancers have a 
good prognosis with 89.9% survival at 5 years for stage I, whereas this rate drops 
to 71.1% in the case of lymph node involvement [11]. 
Unfortunately, 21% of patients with CRC present a metastasis at diagnosis and 
about 50% will eventually metastasize, that is what explains the high rate of 
mortality in these conditions [11, 16] and justifies prevention, mass screening and 
the organization of public awareness campaigns for greater adherence to screening 
programs [17]. 






4. Precancerous lesions 
The adenomatous polyp 
It is a benign epithelial tumor, prevalent in the general population [18] and more 
common in men than in women. According to the data of the autopsies, one-third 
of the population presents an adenomatous polyp [2, 19]. The term polyp is 
unsuitable for an adenoma because a polyp may not be adenomatous. An only 
pathological examination can determine the type of polypoid lesion. 
Up to 80% of colorectal cancers result from the malignant transformation of an 
adenomatous polyp with a first step in the genesis of the adenoma followed by its 
growth and then its malignant degeneration [20]. 
Among 1000 adenomas, only 100 will reach the size of 1 cm and 37 will increase 
in size [2]; an invasive carcinoma is found in 9.3% after a follow-up of 108 
months, and the cumulative risk of malignancy is 2.5% at 5 years, 8% at 10 years 
and 24% to 20 years [21]. 
The size is a major risk factor for malignant transformation. This risk is 0.3% for 
an adenoma less than 1 cm, 9% for an adenoma of size between 1 and 2 cm and 
28% for adenomas greater than 2 cm [2]. 
In addition to size, which is an important element of transformation, we must 
consider the histological types (presence of villous component) and the presence 
of severe dysplasia [18, 22]. 
It is estimated that ten years is the time required for an adenomatous polyp to 
degenerate, that is why 10 years is the time interval for screening after a first 
normal colonoscopy [23]. 
Serrated polyps [24-28] 
According to the World Health Organization WHO classification [27, 29], it is a 
heterogeneous group consisting of three different entities with different malignant 
evolution potential: 
-  Hyperplastic polyps  
They are very common, representing 75% of serrated polyps. These polyps have 
no potential for degeneration. 
- Sessile Serrated Adenoma 
It represents 15 to 20% of serrated polyps with 90% in the right colon. It occurs in 
09% of people who have been colonoscopically examined and are more frequent 
in women. The risk of transformation is lower than that of a conventional 
adenoma but the transformation is faster in the case of occurrence of dysplasia or 
a size greater than 1 cm. In this case, the existence of a synchronous degeneration 
is important and explains why the interval of surveillance between 2 endoscopies 
is different for the two types of polyps, namely classic or adenomatous and 
serrated. 
-  The traditional serrated adenoma  
It is rare, with a potential for degeneration. 
Environmental risk factors and co-morbidities 
These are lifestyle factors. They are modifiable and increase the risk of cancer, 
mainly for the average risk group. 
-Alcohol consumption 






It increases the risk of colorectal cancer without any difference between the 
colonic or rectal locations and this risk increases according to the quantity 
ingested and the duration of consumption, the risk increases by 15% for a 
consumption increase of 100 gr per week [30]. 
- Smoking 
It is a risk factor for adenomas and colorectal cancers. Compared with non-
smokers, smokers and former smokers have a significantly higher risk of 
colorectal cancer and death, although the risk for rectal cancer is greater and 
evident [31, 32]. 
- Obesity and overweight 
The increase in Body Mass Index is associated with an increased risk of colon 
cancer in both sexes, but this increase is more pronounced for men, whereas BMI 
is a risk factor for the development of rectal cancer, but only in men, which means 
that obesity is a risk factor for CRC that depends on sex and the site [33]. 
- The consumption of meat and sausages 
Red meats [34] (beef, mutton, pork, lamb, goat, and veal) and deli meats (meat 
preserved by smoking, drying, salting or adding preservatives) are criminalized. 
The risk is increased by 29% for a 100 gr portion of red meat per day and 21% for 
a 50 gr portion of deli meats per day [35-37]. 
5. Average risk group 
Everyone is at average risk from the age of 50 [38-40]. Age increases, by itself, 
the risk of colorectal cancer [41]. The risk of a population of 50 to 75 years of 
developing colorectal cancer without any other risk factor is estimated between 
3.5 [2] and 4.5% [6]. 
People at average risk eligible for screening: 
- Men and women between 50 and 74 years old. 
- Asymptomatic people at risk Medium: 
• No family history of CCR. 
• No personal history of adenoma, serrated polyp or CCR. 
• No personal history of chronic inflammatory diseases of the intestine. 
- Absence of colonoscopy within 5 years. 
- No search for occult blood in stools dating from less than 2 years. 
- Absence of serious damage to the general condition by another cancer, for 
example, making this test useless. 
Ineligible persons 
- Negative complete colonoscopy within 5 years or Hemoccult test in the previous 
12 months. 
-Symptomatology requiring exploration by colonoscopy: rectorrhagia, melaena, 
recent unexplained abdominal pain especially after 50 years old and transitory 
disorders of recent occurrence in the form of unusual diarrhea or constipation. 
- Increased and very high-risk levels requiring specific monitoring. 
Means of screening 
1) Screening by stool tests "Stool-Based Tests" 






They consist of looking for occult blood in the stool by guaiac test (gFOBT of 
Fecal Occult Blood Test), or by immunological test (Fecal Immunochemical Tests 
(FITs) or iFOBT) and in the search for alterations of the abnormal exfoliated 
DNA (search for the APC gene mutation). These tests are not invasive and require 
no preparation. 
2) Endoscopy: This can be a total colonoscopy or rectosigmoidoscopy. 
3) Virtual colonoscopy. 
Screening strategies 
In the US, where colonoscopy is the primary means of screening [38, 42], four 
strategies are possible with the same survival gain and an equal benefit ratio risk 
[39, 40]: 
- Colonoscopy every 10 years. 
- stool test: annual fecal occult blood test by guaiac test or immune-histochemical 
test (FIT) or by FIT coupled with the abnormal DNA test every three years. 
- Sigmoidoscopy every 5 to 10 years with possibly the annual test (FIT). 
- Virtual colonoscopy (VC) every 5 years. 
Some countries like France perform mass screening in two stages. The first is that 
of selection by the search for occult blood in the stool (currently the 
immunological test). In case of positive test and in a second time called 
"diagnosis" a colonoscopy is performed. 
This approach is based on the argument that a first-intention colonoscopy will 
have a very high rate of negative colonoscopies so that this examination no longer 
meets the criteria required for screening. 
6. Evolution of ideas 
However, this (French) vision could not ignore the fact that colonoscopy reduced, 
although more for the distal than proximal colon, mortality and the incidence of 
colorectal cancers [43, 44]. Thus, a colonoscopy of Prevention could be carried 
out on an individual basis in an average-risk subject after informing him about the 
advantages and disadvantages of the examination and obtaining his informed 
consent [45]. 
In addition, the so-called average risk population is very heterogeneous because 
people in this group are exposed in a different way to environmental factors and 
co-morbidities. Some of them are close to the high-risk group; they are identified 
by means of scores [46] and assigned to colonoscopy screening from the outset 
[45]. This evolution of ideas in France is close, at least for one category of 
subjects, to the American attitude that proposes, from the start, endoscopy as a 
means of screening and prevention.  
7. Discussion 
The incidence, morbidity, and mortality of CRCs justify their prevention and mass 
screening. For this purpose, colonoscopy is the gold standard. If colonoscopy was 
performed as a first-line treatment for the entire population over the age of 50, the 
high rate of negative examinations would no longer allow endoscopy to meet the 
required criteria for screening. The severity of this disease, the performance of 






colonoscopy on the left colon and the higher frequency of CRCs on the left (2/3 of 
colon cancers) allowed the emergence of rectosigmoidoscopy as a good 
alternative. Indeed adenomatous polyps are the most common precancerous lesion 
on the left, and the detection rate depends on the expertise of the endoscopist. In 
the right colon, serrated polyps are the most common precancerous lesion. These 
serrated polyps including sessile serrated adenomas are difficult to locate, and an 
endoscopist with a high rate detection of adenomatous polyps does not necessarily 
have the same expertise for serrated polyps. Virtual colonoscopy also faces the 
difficulty of detection of these polyps. In the USA, screening strategies have 
multiplied to overcome the invasive nature of colonoscopy. All strategies take into 
account epidemiological and pathological data. 
In France, as in other countries, stool testing is not enough for some people who 
theoretically belong to the average risk group. Environmental factors and / or co-
morbidities rank them in the high-risk group. These people, outclassed, will 
benefit from individual screening. Regardless of these environmental factors and 
co-morbidities, it is possible to propose a colonoscopy in an average-risk person 
after obtaining informed consent. 
8. Conclusion  
The effectiveness of CRC screening in the average-risk group is clear. Screening 
with fecal occult blood testing has proven effectiveness; this one is, however, 
inferior to that of endoscopy. This risk group is no longer considered a 
homogeneous group, and among this group, some subjects are considered high 
risk, and they are entrusted with endoscopic screening. In middle-risk people, we 
can say "true average-risk group" screening must find a tradeoff between benefit 
and risk. The VC can be used as a non-invasive means. It is sensitive and specific 
for polyps greater than 1 cm that have a risk of degeneration. In case of 
particularly multiple lesions and a size larger than 1 cm, a colonoscopy must be 
performed and the right colon is de facto explored. Regarding right colon lesions, 
where serrated polyps are more common, the VC is not very sensitive. This 
difficulty of detection being also posed to the colonoscopy; it would perhaps be 
justified to propose a search for abnormal DNA or Fecal Immunochemical Tests 
(FITs) in the saddle in case of negative VC in order to limit the number of lesions 
missed on the right and thus to decrease the interval cancers. 
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